Silexion Therapeutics (SLXN) Change in Account Payables (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Change in Account Payables of $125000.0 for Q1 2026, up 160.39% year-over-year from $48005.6 in Q1 2025, and up 178.62% quarter-over-quarter from -$159000.0 in Q4 2025.
Silexion Therapeutics (SLXN) Change in Account Payables (2023 - 2026) Analysis & Trends
Silexion Therapeutics' Change in Account Payables history runs 4 years deep, the most recent figure standing at $125000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 160.39% year-over-year to $125000.0; the TTM figure through Mar 2026 stood at $190000.0 (down 60.25% YoY), while the FY2025 annual figure was -$142000.0, down 123.28% from the prior year.
- Change in Account Payables for Q1 2026 stood at $125000.0, up from -$159000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $517000.0 in Q3 2024, with the low at -$207000.0 in Q1 2025.
- The 4-year median for Change in Account Payables is $21000.0 (2023), against an average of $56416.7.
- The sharpest annual moves came in 2024 and 2025: Change in Account Payables jumped 2520.0% in 2024, then tumbled 221.37% in 2025.
- Silexion Therapeutics' Change in Account Payables stood at $5000.0 in 2023, then surged by 2520.0% to $131000.0 in 2024, then sank by 221.37% to -$159000.0 in 2025, then surged by 178.62% to $125000.0 in 2026.
- Business Quant data shows SLXN's Change in Account Payables at $125000.0 in Q1 2026, -$159000.0 in Q4 2025, and $254000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Silexion Therapeutics | 266,692.97 | -1.96 Mn | - | 268,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 268,000.00 |
| Jun 30, 2026 | 268,000.00 |
| Mar 31, 2026 | 125,000.00 |
| Mar 31, 2026 | 125,000.00 |
| Dec 31, 2025 | -159,000.00 |
| Dec 31, 2025 | -159,000.00 |
| Sep 30, 2025 | 254,000.00 |
| Sep 30, 2025 | 254,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Mar 31, 2025 | -207,000.00 |
| Mar 31, 2025 | -207,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Sep 30, 2024 | 517,000.00 |
| Sep 30, 2024 | 517,000.00 |
| Jun 30, 2024 | 37,000.00 |
| Jun 30, 2024 | 37,000.00 |
| Mar 31, 2024 | -75,000.00 |
| Mar 31, 2024 | -75,000.00 |